Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Blind, Multi-centre, Randomised Multinational Phase III Study to Compare the Efficacy and Tolerability of Anagrelide vs Hydroxyurea in Patients With Essential Thrombocythaemia

NCT01065038 is registered in ClinicalTrials.gov with AOP Orphan Pharmaceuticals AG as lead sponsor.

NCT NCT01065038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01065038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Blind, Multi-centre, Randomised Multinational Phase III Study to Compare the Efficacy and Tolerability of Anagrelide vs Hydroxyurea in Patients With Essential Thrombocythaemia
Lead sponsor
AOP Orphan Pharmaceuticals AG
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2002
Completion date
Not reported
Enrollment
Not reported
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

essential thrombocythaemia